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Myopia is one of the leading causes of visual impairment globally. Despite increasing
prevalence and incidence, the associated cost of treatment remains unclear. Health
care spending is a major concern in many countries and understanding the cost of
myopia correction is the first step eluding to the overall cost of myopia treatment. As
cost of treatment will reduce the burden of cost of illness, this will aid in future cost-
benefit analysis and the allocation of healthcare resources, including considerations in
integrating eye care (refractive correction with spectacles) into universal health coverage
(UHC). We performed a systematic review to determine the economic costs of myopia
correction. However, there were few studies for direct comparison. Costs related to
myopia correction were mainly direct with few indirect costs. Annual prevalence-based
direct costs for myopia ranged from $14-26 (USA), $56 (Iran) and $199 (Singapore)
per capita, respectively (population: 274.63 million, 75.15 million and 3.79 million,
respectively). Annually, the direct costs of contact lens were $198.30-$378.10 while
spectacles and refractive surgeries were $342.50 and $19.10, respectively. This review
provides an insight to the cost of myopia correction. Myopia costs are high from nation-
wide perspectives because of the high prevalence of myopia, with contact lenses being
the more expensive option. Without further interventions, the burden of illness of myopia
will increase substantially with the projected increase in prevalence worldwide. Future
studies will be necessary to generate more homogenous cost data and provide a
complete picture of the global economic cost of myopia.
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INTRODUCTION
Myopia is one of the leading causes of visual impairment in the world (1, 2). The prevalence of
myopia ranges from 15 to 49% in adult populations, and ranges from 20 to 90% in children,
adolescents and young adults (3–7). Studies estimate that myopia will affect 50% (4.7 billion) of
the world’s population by 2050, with 10% (1 billion) having high myopia (≤-5.00 Dioptres) (8–
10) Correction of myopia with spectacles, contact lenses and refractive surgeries therefore play an
increasingly important role in society, as uncorrected myopia results in reduction of visual acuity
leading to impaired visual functioning (11).
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However, there are significant costs associated with optical
correction, treatment to retard myopia progression and
treatment of myopia related complications, including pathologic
myopia, cataract, glaucoma and retinal detachment (12–16).
With increasing demand for the limited healthcare resources
globally, an understanding of the economic cost associated with
the treatment of myopia is important for further cost-benefit
analysis and policy making decisions. This will aid and justify in
the allocation of invaluable healthcare resources to the treatment
of myopia, in order to reduce the economic burden of this illness.
We aim to perform an evidence-based review of the economic
costs associated with the correction of myopia.
SOURCES AND METHODS OF
LITERATURE SEARCH
We conducted a systematic review of relevant literature
articles in accordance with the Preferred Reporting Items for
Systematic Reviews andMeta-analysis (PRISMA) guidelines (17).
Several electronic databases (PubMed, ScienceDirect, Cochrane
Library, and Web of Science databases) were searched to
identify English language articles up to 29 February 2020
on costs associated with myopia correction treatment. The
search used the keywords “myopia,” “short-sightedness” or
“near-sightedness” combined with “cost” or “economic burden.”
Original full-text articles in English were included if costs were
quantified in relation to myopia correction, including: myopia
correction (spectacles, contact lenses, refractive surgeries). 8,492
titles were retrieved through database searching. Forty five
relevant records were reviewed with 12 records excluded (9
duplicates and 3 with no full-text available). Fifteen full-
text articles were assessed for eligibility with 2 non-English
articles excluded (articles in German). Articles that did not
fulfill the inclusion criteria were excluded. Five eligible full-
text articles were included in this review (18–22). The review
article selection process is illustrated as a flowchart in Figure 1.
The Asian studies comprised of 2 from Singapore while
the non-Asian studies comprised of one from each of the
following countries: United States of America (USA), Iran
and Spain.
A 20-items Consensus Health Economic Criteria (CHEC)-
extended checklist was used to evaluate the overall quality of
included studies (23, 24). Scoring was performed by assigning
a score of 1 (yes), 0 (no), 2 (not applicable) to each item and
the total scores were summed to generate the overall quality
score (0–100%). The total quality score for each study was
categorized into low, moderate, good and excellent with cut-
off value of <50, 51–75, 76–95 and >95, respectively. Only
moderate, good and excellent quality studies were included
as higher scores denote lower risk of bias. Two independent
reviewers conducted the assessment (LLF and CL) and the
interrater-agreement was evaluated using κ from STATA/IC 11.1
(25). The interpretation of the κ was based on a scale which
indicates poor, slight, fair, moderate, substantial and perfect
agreement with κ levels <0.0, 0.0–0.20, 0.21–0.40, 0.41–0.60,
0.61–0.80 and ≥0.81, respectively (26). Of the included studies,
4 were good in quality (76.5–95) and 1 was excellent (100).
The interrater-reliability κ was moderate in 1 study (0.44),
substantial in 2 studies (0.63, 0.64) and perfect in 2 studies
(1, 1).
Examples of costs assessed included optical correction
devices/procedures (spectacles, contact lenses, refractive
surgeries), visits to professional services (transportation and fees)
and time spent and loss of productivity while seeking treatment.
All costs are quoted in US dollars ($). Conversion rate used
was Euro to USD= 1:1.12 (22, 27) and Pound sterling to USD=
1:1.31 (28), using average 2019 exchange rates (29).
RESULTS
The costs for myopia correction are shown in Table 1.
The average direct costs of myopia correction in Singapore
children aged 12–17 years from the SCORM study (Singapore
Cohort study of the Risk factors ofMyopia) were $147.80 per year
per myopia patient, $82.10 per pair of spectacles and $378.10 per
year for contact lenses (18).
In Singapore adults aged ≥40 years, the mean direct cost of
myopia correction was $709 per year per patient. This estimate
translates into an annual economic burden of $755 million
in Singapore. Refractive correction, comprising of optometry
visits, spectacles and contact lenses, were the most significant,
accounting for 65.2% of the total costs (19). The remaining costs
comprise of refractive surgeries and complications related to it as
well as contact lens use.
In USA, the annual direct country-wide cost of correcting
distance vision impairment was estimated to be between
$3.9 and $7.2 billion, with $780 million per annum for
persons >age 65 years (33). The National Health and
Nutrition Examination Survey (NHANES) was an ongoing,
nationally representative survey of 14,203 participants aged
≥ 12 years (32, 33). The cost calculations were based on
single-vision spectacles, without including other refractive
correction options. Hence, this cost would be much higher
if contact lenses and refractive surgeries were taken into
account. As the annual costs from the earlier Singapore
study were based on all forms of corrections, direct
comparison is inequitable. In addition, due to the study’s
methodology for distant vision correction, subjects with
pure astigmatism without myopia were also included in the
cost calculations.
In two other studies (21, 22), the costs of refractive
correction were computed by including other refractive errors
(hyperopia and astigmatism). While the costs of each modality
for myopia correction alone could not be determined, they
provide insights to the general cost for refractive correction in
the country.
In a Spanish study, the direct cost of spectacles, contact
lenses and LASIK were evaluated (22). It was reported that
the total direct (medical and non-medical) cost over 10, 20,
and 30 years (5% discount rate) for contact lens was $3019.64;
4723.21; 5779.46, LASIK was $3341.96; 3368.75; 3385.71 and
spectacles was $1091.07; 1623.21; 1960.71 (22). This was a
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FIGURE 1 | Flowchart of the review article selection process.
small study of 40 subjects from one city in Alicante, with
80% myopes (12.5% hyperopes and 42.5% astigmatic). This
study was conducted in 2002 and hence costs might not be
representative of the current market, particularly the cost of
cleaning and fitting contact lens and transport system with
technological advancements.
In a recent Iranian study, 120 subjects aged ≥ 23 years
were interviewed in a hospital and the lifetime direct costs
of spectacles, contact lenses and refractive surgeries were
$9373.50, $5203.10, and $568.10, respectively (21). The annual
direct costs of refractive correction per patient and for each
of the three modalities were $309, $342.50, $198.30, and
$19.10, respectively. Annually, direct cost of myopia correction
was estimated to be $4.2 billion in Iran. Indirect costs in
this study were estimated using the human capital approach,
by ascertaining lost productivity due to the complication,
maintenance, repair and travel costs as a measure of patient’s
and caregiver’s lost earnings (34). Annually, the indirect costs
were $12112.10, $3045.20, and $113.60, respectively with the
main bulk contributed by patient’s and caregiver’s opportunity
cost. However, it was not clear from the study regarding
the basis and role of caregiver’s costs calculation in optical
correction and no justification was offered for the high
indirect costs from spectacles, considering it is least prone to
complications. In addition, cost calculations for each refractive
correction modality were generalized to all forms of refractive
errors, it was challenging to estimate the cost generated from
myopia only.
Out of the three groups of myopia correction modalities
reported in the studies (18, 21, 22), contact lens and spectacles
appeared to be generally more costly than refractive surgeries
(Figure 2). Annually, the direct costs of contact lens and
spectacles were $198.30-$378.10 and $342.50, respectively while
refractive surgeries was $19.10 (18, 21).
In Singapore, while the annual direct cost of myopia
correction to the individual is the lowest compared to diabetic
retinopathy and wet age-related macular degeneration (AMD)
(18, 19, 35, 36), the nation’s annual direct cost of myopia
correction ($755million) alone far exceeded other ocular diseases
including acute primary angle closure glaucoma ($0.26–0.29
million), dry eyes ($1.51–1.52 million) and wet AMD ($96.8–
120.7 million) (Table 2) (18, 19, 35, 36, 41, 42).
DISCUSSION
In this review, we found 5 studies addressing the cost of myopia
correction (18, 19, 21, 22, 33), which are generally direct costs
from spectacles, contact lens and refractive surgeries. The per
capita annual cost of myopia correction was low in USA,
moderate in Iran and high in Singapore. Indirect costs in myopia
correction are mainly related to complications, particularly with
contact lens use, including cost of treatment, loss of productivity
secondary to complications and its associated travel costs (21).
We found that the annual direct costs of myopia correction in
USA, Iran and Singapore were substantial at $3.9–7.2 billion,
$4.2 billion and $755 million, respectively. This translated to
$14–26 (USA), $56 (Iran) and $199 (Singapore) per capita,
respectively (population: 274.63 million, 75.15 million and 3.79
million, respectively) (19, 21, 43). Most costs related to myopia
correction were direct costs, with contact lens appearing to be
generally more costly compared to other modalities.























TABLE 1 | Summary table of reviewed articles (treatment of Myopia-Myopia correction: n = 5).
Treatment of Myopia (Myopia correction)

















301 12–17 Parent and
Self
questionnaire
NA Annual direct cost
Mean (Per patient) = $147.8
± 209.1 (CI, $124.3–172.1)
Median (Per patient) =
$83.3
Mean cost per pair of
spectacles
$82.1 ± 40.8 (CI,
$77.8–86.5)
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Spectacles = $ 1091.07;
1623.21; 1960.71











































































TABLE 1 | Continued
Treatment of Myopia (Myopia correction)









Direct cost ($) Indirect cost ($)











Total annual direct cost*
Spectacles = $342.5 ±
8.41
Contact lenses = $198.30
± 0.12
Refractive surgery = $19.10
± 1.2
Lifetime direct cost*
Spectacles = $9373.5 ±
230.1
Contact lenses = $5203.10
± 256.3
Refractive surgery = $568.1
± 64.6
Annual direct cost*
Mean (Per patient) = $309
Annual direct cost
All ages = $4.2 billion
Persons age < 14 = $196
million
Persons age 15-19 = $337
million
Persons age 20-29 =
$3043 million
Persons age > 60 =
$628.55 million
Total annual indirect cost*
Spectacles = $12112.10









Annual and lifetime total costs* (direct
and indirect)
Spectacles = $12454.6; 340754.10,
Contact lenses = $3243.5; 84965.30
Refractive surgery = $132.7; 3357.20
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FIGURE 2 | Cost of myopia correction modalities (Refractive surgeries, Spectacles, Contact lens).
TABLE 2 | Cost of ocular diseases in Singapore.
Eye diseases in Singapore Annual direct cost in Singapore ($) Mean annual direct cost per patient ($)
Diabetic retinopathy (37) NA $863.65–2660.15
Acute primary angle closure glaucoma (38) $0.26–0.29 million NA
Dry eyes (39) $1.51–1.52 million* NA
Wet AMD (40) $96.8–120.7 million $6902.20
Myopia correction (27, 30) $755 million $147.80–709
*Singapore National Eye Centre only.
We found few studies to adequately address this topic
and limited studies using similar costs definitions for
comparison. Firstly, there was a limited representation
of studies globally, with 2 from Asia (Singapore)
and 3 from Europe (Spain), USA and Middle East
(Iran), respectively. Secondly, different methodologies
and cost definitions were used for cost calculations
and many studies did not assessed indirect costs
in detail.
The World Health Organization (WHO) considers spectacles
or contact lenses as functioning interventions (44), with
spectacles being also considered as an assistive device which
is part of the WHO Priority Assistive Products List (45). As
health care spending is a major concern in many countries,
understanding the cost of myopia correction is the first step
eluding to the overall cost of myopia treatment. Moreover,
among the worldwide population with moderate or severe vision
impairment, uncorrected refractive error was the highest at
116.3 to 123.7 million (46, 47), with the cost of coverage gap
for unaddressed refractive error and cataract estimated to be
$14.3 billion globally (45). As cost of treatment will reduce the
burden of cost of illness, this will aid in future cost-benefit
analysis and the allocation of healthcare resources, including
considerations in integrating eye care (refractive correction
with spectacles) into universal health coverage (UHC) (45).
This is particularly important in Asian developing countries
where there is high prevalence of myopia with low accessibility
to spectacles.
Although the cost of myopia to an individual may not be
very high, the cost of myopia to the nation is one of the
highest as the prevalence of myopia is higher than many other
diseases. The high prevalence of myopia plays an important
role in determining the economic cost of the treatment of
myopia in each country. In East and Southeast Asia, the
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prevalence of myopia was reported to be as high as 80–
90% in adolescents of age of 17–18 (7). In contrast, 20–40%
was reported in developed western countries (7, 20, 40, 48–
50). Hence while the magnitude of direct cost of refractive
correction was greater in USA and Iran than in Singapore,
the per capita cost was lesser at $14–26 and $56 vs. $199 (19,
31).
Other factors that could account for variation in costs
include country-specific costs, different methodologies, study
subject’s characteristics (including age), timeline, varying costs
of living and socioeconomic status. However, due to limited
studies available, it would be challenging to explore the influence
of these factors. As the governments in most countries are
unlikely to be able to monitor spectacle or contact lens
sales, future cost data can be obtained by considering cross-
sectional rapid assessment protocols, targeting for instance
high schools.
In Singapore, although the annual direct cost of myopia
correction to the individual is lowest amongst diabetic
retinopathy and wet AMD (18, 19, 35, 36), the nation’s
annual direct cost of myopia correction alone far exceeded
other ocular diseases including acute primary angle closure
glaucoma, dry eyes and AMD (18, 19, 35, 36, 41, 42). This
finding is not surprising and is attributed to the high prevalence
of myopia in the country, with myopia expected to remain as
the most common ocular condition with 2.393 million cases in
2040 (51).
Out of the three groups of myopia correction modalities,
contact lens and spectacles seemed to be generally more costly
than refractive surgery (18, 21, 22), with the exception of 1
study which did not justify the inclusion of high patient and
caregiver opportunity costs from spectacles use (21). This is
excluding the indirect costs of contact lens related complications
(e.g., infective keratitis), including cost of treatment, loss of
productivity secondary to complications and its associated travel
costs. However, this cost is expected to be dynamic in view
of technological advancement, economic forces, occupational
and recreational requirements, individuals paying premium for
factors such as aesthetics and quality as well as free or subsidized
refractive correction by the government.
Contact lenses were mainly prescribed for the correction of
myopia, with proportion as high as 94% (52). The three key
cost components of contact lens wear are the professional fees,
the cost of lenses and the cost of lens care solutions (38, 39).
Spherical lenses have the lowest overall cost, followed by toric
and multifocal lenses (39), with the true cost of lens wear (cost-
per-wear) dependent on the frequency of use (38, 39). Generally,
daily replacement contact lenses aremore cost-effective on a part-
time usage, while reusable lenses are more cost-effective on a
full-time usage (38). With contact lens gaining popularity among
the teenagers and young adults (52), together with the high
prevalence of myopia in this age-group (3–7), the nation-wide
costs of contact lenses are expected to rise in the near future.
We have reviewed the costs of optical correction of myopia.
However, since the cost and burden to the nation is high,
treatments to slow myopia progression and measures to prevent
myopia and high myopia (including outdoor programs) are
important to reduce the prevalence of myopia and subsequent
costs of illness, including burden related to its complications.
Atropine eyedrops have shown strong evidence in myopia
control while Orthokeratology, myopic defocus multizone
contact lenses and spectacles have shown some effect (30, 37,
53–57). However, there is currently no literature reporting
the treatment costs generated from Atropine use in children
(53, 54). The use of myopia control treatment modalities will
inevitably incur costs including equipment, professional services
and the management of complications, particularly infective
keratitis with contact lens use. Further studies, including cost-
effectiveness randomized control trials of treatments for myopia
progression will be necessary to evaluate this knowledge deficit.
LIMITATIONS
For myopia correction, differentiating costs of optometry visits
and refractive correction devices was difficult due to difference in
studie’s methodology. Another limitation includes the presence
recall and non-response bias from retrospective design studies
and the use of questionnaires/interviews. In addition, cost data
reported in older studies may not be a reliable reflection of today’s
costs, due to various economic factors. Details of indirect costs
were lacking. There were few studies available in the literature
with limited representation globally.
FURTHER STUDIES
Future studies will be necessary to generate a more homogenous
cost data and provide a more complete picture of the global
economic cost of myopia treatment. These include cost of illness
analysis, programmatic costs of spectacles correction in rural
areas by non-governmental organizations and cost-effectiveness
randomized control trials of treatments for myopia progression.
CONCLUSION
Our systematic review provides insight on the costs of myopia
correction. Annual prevalence-based direct costs for myopia
correction are substantial, ranging from US$14–26 (USA), $56
(Iran) to $199 (Singapore) per capita. In Singapore, the annual
direct cost of myopia correction alone far exceeded the costs
of other ocular diseases including acute primary angle closure
glaucoma, dry eyes and wet AMD due to high prevalence of
disease. Without further interventions, the economic burden of
illness of myopia will increase substantially with the projected
increase in prevalence worldwide. Hence, myopia control
treatment in children and measures to prevent myopia and
high myopia will play an increasingly important role to reduce
prevalence and costs of illness. Future studies will be necessary to
generate a more homogenous cost data and provide a complete
picture of the global economic cost of myopia.
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